Works matching 5Q deletion syndrome
Results: 123
Suspected Immune Thrombocytopenic Purpura Induced by Lenalidomide for the Treatment of Myelodysplastic Syndrome with Deletion of Chromosome 5q: A Case Report.
- Published in:
- Tohoku Journal of Experimental Medicine, 2023, v. 259, n. 2, p. 113, doi. 10.1620/tjem.2022.J104
- By:
- Publication type:
- Article
Evolution of severe (transfusion‐dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophage‐associated failure of the eythropoietic niche.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 1, p. 114, doi. 10.1111/bjh.18163
- By:
- Publication type:
- Article
Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency.
- Published in:
- European Journal of Haematology, 2018, v. 101, n. 1, p. 78, doi. 10.1111/ejh.13067
- By:
- Publication type:
- Article
APC -Related Phenotypes and Intellectual Disability in 5q Interstitial Deletions: A New Case and Review of the Literature.
- Published in:
- Genes, 2023, v. 14, n. 7, p. 1505, doi. 10.3390/genes14071505
- By:
- Publication type:
- Article
Clinicopathological characteristics of myelodysplastic syndromes with del(5q) in Taiwan.
- Published in:
- Malaysian Journal of Pathology, 2023, v. 45, n. 3, p. 405
- By:
- Publication type:
- Article
Utilisation des analogues de la thalidomide dans le traitement des hémopathies malignes.
- Published in:
- Hematologie, 2022, v. 28, n. 1, p. 55, doi. 10.1684/hma.2022.1718
- By:
- Publication type:
- Article
Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene.
- Published in:
- 2016
- By:
- Publication type:
- journal article
SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Autoimmune Disorders in Two Patients with Myelodysplastic Syndrome and 5q Deletion.
- Published in:
- Acta Haematologica, 2005, v. 113, n. 2, p. 146, doi. 10.1159/000083454
- By:
- Publication type:
- Article
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q).
- Published in:
- 2021
- By:
- Publication type:
- journal article
Response to lenalidomide in patients with myelodysplastic syndrome with deletion 5q: clinical and cytogenetic analysis of a single centre series.
- Published in:
- 2010
- By:
- Publication type:
- Letter
The CRBN, CUL4A and DDB1 Expression Predicts the Response to Immunomodulatory Drugs and Survival of Multiple Myeloma Patients.
- Published in:
- Journal of Clinical Medicine, 2021, v. 10, n. 12, p. 2683, doi. 10.3390/jcm10122683
- By:
- Publication type:
- Article
Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.
- Published in:
- British Journal of Haematology, 2014, v. 166, n. 2, p. 189, doi. 10.1111/bjh.12876
- By:
- Publication type:
- Article
Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q.
- Published in:
- Leukemia (08876924), 2015, v. 29, n. 9, p. 1942, doi. 10.1038/leu.2015.49
- By:
- Publication type:
- Article
Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide.
- Published in:
- 2012
- By:
- Publication type:
- Letter
Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Low frequency of the glutathione-S-transferase T1-null genotype in patients with primary myelodysplastic syndrome and 5q deletion.
- Published in:
- 2008
- By:
- Publication type:
- Letter
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS).
- Published in:
- Journal of Hematology & Oncology, 2012, v. 5, n. 1, p. 18, doi. 10.1186/1756-8722-5-18
- By:
- Publication type:
- Article
Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion.
- Published in:
- Oncogene, 2013, v. 32, n. 9, p. 1110, doi. 10.1038/onc.2012.139
- By:
- Publication type:
- Article
Molecular pathogenesis of myelodysplastic syndromes with deletion 5q.
- Published in:
- European Journal of Haematology, 2019, v. 102, n. 3, p. 203, doi. 10.1111/ejh.13207
- By:
- Publication type:
- Article
Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.
- Published in:
- European Journal of Haematology, 2010, v. 85, n. 3, p. 231, doi. 10.1111/j.1600-0609.2010.01473.x
- By:
- Publication type:
- Article
Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis.
- Published in:
- PLoS ONE, 2016, v. 11, n. 11, p. 1, doi. 10.1371/journal.pone.0165948
- By:
- Publication type:
- Article
Lenalidomide: A Review of its Use in Patients with Transfusion-Dependent Anaemia due to Low- or Intermediate-1-Risk Myelodysplastic Syndrome Associated with 5q Chromosome Deletion.
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
MDS mit Deletion 5q: Eine Sonderform myelodysplastischer Syndrome.
- Published in:
- Therapeutische Umschau, 2022, v. 79, n. 2, p. 87, doi. 10.1024/0040-5930/a001333
- By:
- Publication type:
- Article
Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01027-5
- By:
- Publication type:
- Article
Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 9, p. 1, doi. 10.1038/s41408-022-00724-3
- By:
- Publication type:
- Article
Chronic GVHD induced GVL effect after unmanipulated haploidentical hematopoietic SCT for AML and myelodysplastic syndrome.
- Published in:
- Bone Marrow Transplantation, 2015, v. 50, n. 1, p. 127, doi. 10.1038/bmt.2014.223
- By:
- Publication type:
- Article
Deregulation of innate immune signaling in myelodysplastic syndromes is associated with deletion of chromosome arm 5q.
- Published in:
- Cell Cycle, 2010, v. 9, n. 5, p. 855, doi. 10.4161/cc.9.5.11156
- By:
- Publication type:
- Article
A paediatric myelodysplastic syndrome with 5q deletion associated with Fanconi anaemia.
- Published in:
- 2020
- By:
- Publication type:
- Case Study
Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.
- Published in:
- Annals of Hematology, 2014, v. 93, n. 5, p. 723, doi. 10.1007/s00277-014-2022-3
- By:
- Publication type:
- Article
Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion.
- Published in:
- 2012
- By:
- Publication type:
- Letter
Hemophilia B in a female with intellectual disability caused by a deletion of Xq26.3q28 encompassing the F9.
- Published in:
- Molecular Genetics & Genomic Medicine, 2018, v. 6, n. 6, p. 1220, doi. 10.1002/mgg3.425
- By:
- Publication type:
- Article
Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations.
- Published in:
- Mycoses, 2015, v. 58, n. 9, p. 565, doi. 10.1111/myc.12357
- By:
- Publication type:
- Article
Cryptic 5q deletion in a patient with myelodysplastic syndrome.
- Published in:
- British Journal of Haematology, 2017, v. 177, n. 3, p. 347, doi. 10.1111/bjh.14590
- By:
- Publication type:
- Article
CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q).
- Published in:
- British Journal of Haematology, 2015, v. 171, n. 2, p. 210, doi. 10.1111/bjh.13563
- By:
- Publication type:
- Article
L-Leucine improves the anaemia in models of Diamond Blackfan anaemia and the 5q- syndrome in a TP53-independent way.
- Published in:
- British Journal of Haematology, 2014, v. 167, n. 4, p. 524, doi. 10.1111/bjh.13069
- By:
- Publication type:
- Article
Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.
- Published in:
- British Journal of Haematology, 2012, v. 156, n. 5, p. 619, doi. 10.1111/j.1365-2141.2011.08979.x
- By:
- Publication type:
- Article
Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion.
- Published in:
- 2010
- By:
- Publication type:
- Letter
Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents.
- Published in:
- Leukemia (08876924), 2013, v. 27, n. 6, p. 1283, doi. 10.1038/leu.2013.16
- By:
- Publication type:
- Article
Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Hematological features of patients with myelodysplastic syndromes associated with a chromosome 5q deletion.
- Published in:
- American Journal of Hematology, 1995, v. 49, n. 3, p. 194, doi. 10.1002/ajh.2830490304
- By:
- Publication type:
- Article
Interstitial deletion of chromosome 5, del(5q), in a newborn with down syndrome and an unusual hematologic disorder.
- Published in:
- American Journal of Hematology, 1989, v. 31, n. 4, p. 273, doi. 10.1002/ajh.2830310412
- By:
- Publication type:
- Article
Durable response to lenalidomide in a patient with myelodysplastic syndrome associated with isolated 5q deletion and JAK2 V617F mutation despite discontinuation of treatment.
- Published in:
- 2016
- By:
- Publication type:
- Case Study
Active treatment strategies improving outcomes in patients with myelodysplastic syndromes with the deletion 5q abnormality.
- Published in:
- 2008
- By:
- Publication type:
- Journal Article
Active Treatment Strategies Improving Outcomes in Patients with Myelodysplastic Syndromes with the Deletion 5q Abnormality.
- Published in:
- Clinical Cancer Update, 2008, v. 2, n. 1, p. 58, doi. 10.3816/CCU.2008.n.010
- By:
- Publication type:
- Article
Clival Encephalocele and 5q15 Deletion:: A Case Report.
- Published in:
- 2015
- By:
- Publication type:
- Case Study